Replimune (REPL) Invested Capital (2018 - 2025)

Replimune has disclosed Invested Capital across 8 years of filings, most recently posting $235.5 million for Q4 2025.

• Invested Capital for Q4 2025 came in at $235.5 million, down 53.64% year-over-year; the trailing twelve-month figure through Dec 2025 was $235.5 million (down 53.64% YoY), and the FY2025 annual result was $462.2 million, up 10.23% from the prior year.
• Invested Capital came in at $235.5 million for Q4 2025 at Replimune, down from $288.5 million in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $622.0 million in Q4 2022 to a low of $235.5 million in Q4 2025.
• The 5-year median for Invested Capital is $457.3 million (2024), against an average of $451.7 million.
• Across the five-year window, Invested Capital jumped 157.72% in 2021 and plunged 53.64% in 2025, its largest moves.
• Replimune's Invested Capital stood at $464.6 million in 2021, then surged by 33.9% to $622.0 million in 2022, then slipped by 28.01% to $447.8 million in 2023, then advanced by 13.46% to $508.1 million in 2024, then slumped by 53.64% to $235.5 million in 2025.
• The last three Invested Capital figures came in at $235.5 million (Q4 2025), $288.5 million (Q3 2025), and $362.1 million (Q2 2025), per Business Quant data.